Table II.
Progression-free survival with respect to treatment and E-cadherin immunoreactivity.
| Comparison | E-cadherin immunoreactivity <8 | E-cadherin immunoreactivity ≥8 | Log-rank P-value | HRa (95% CI): E-cadherin immunoreactivity ≥8 vs. <8 | Wald chi-square P-valuea |
|---|---|---|---|---|---|
| EB arm: Median PFS in months | 3.9 | 3.0 | 0.7415 | 1.113 (0.588–2.109) | 0.7423 |
| PGB arm: Median PFS in months | 6.9 | 5.6 | 0.3924 | 1.275 (0.729–2.227) | 0.3942 |
| Log-rank P-value | 0.0007 | 0.0626 | – | – | – |
| HRa (95% CI): PGB vs. EB | 0.353 (0.189–0.658) | 0.567 (0.309–1.040) | – | – | – |
| Wald chi-square P-valuea | 0.0011 | 0.0667 | – | – | – |
a
Univariate Cox model. HR, hazard ratio; CI, confidence interval; EB, erlotinib/bevacizumab; PGB, cisplatin/gemcitabine/bevacizumab.